nach oben

Erschienen in:

01.01.2015 | review article

10th anniversary of the Austrian MDS Platform: aims and ongoing projects

verfasst von: Sonja Burgstaller, MD, Peter Bettelheim, Otto Krieger, Sigrid Machherndl-Spandl, Thomas Nösslinger, Lisa Pleyer, Heinz Sill, Wolfgang R. Sperr, Reinhard Stauder, Peter Valent, Michael Pfeilstöcker

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2015

Einloggen, um Zugang zu erhalten

Summary

The Austrian myelodysplastic syndromes (MDS) Platform was founded as a national working group in 2003 to initiate and coordinate common projects in the field. The incidence of MDS in Austria is approximately 400–500 new MDS cases per year. The overall low number of MDS patients underlines the importance of a national initiative to concentrate knowledge at certain specialized centres, where treatment of these patients mainly takes place. Clinical trials as well as basic research are facilitated by the cooperation of university and non-university hospitals. Other objectives are the generation of therapeutic standards, organization of meetings to spread this information to physicians and patients as well as promoting patient-support groups. Cooperation with international working groups is another important aim of the Platform. The 10th anniversary of the Austrian MDS Platform was organized as a meeting for all interested physicians throughout Austria providing an update on the disease and ongoing projects.

Vorheriger Artikel Systematic implementation of clinical risk management in a large university hospital: the impact of risk managers

Nächster Artikel Trichobezoar causing recurrent gastric ulcer and perforation

Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRef

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRef

Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol. 2011;162:792–805.PubMedCentralPubMedCrossRef

Valent P, Horny HP, Bennet JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.PubMedCrossRef

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26:1730–41.PubMedCrossRef

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz M, et al. International scoring system for evaluating prognosis in myelodysplastic sydromes. Blood. 1997;89:2079–88.PubMed

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.PubMedCrossRef

Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2010;21:120–5.PubMedCrossRef

Stauder R, Nösslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;9:927–34.

10.

Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21:114–9.PubMedCrossRef

11.

Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94:729–32.PubMedCentralPubMedCrossRef

12.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef

13.

Sorror ML, Maris MB, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.PubMedCentralPubMedCrossRef

14.

Sperr WR, Kundi M, Wimazal F, Nösslinger T, Schönmetzler-Makrai A, Stauder R, et al. Proposed score for survival of patients with myelodysplastic syndromes. Eur J Clin Invest. 2013;43:1120–8.PubMed

15.

Bammer C, Sperr WR, Kemmler G, Wimazal F, Nösslinger T, Schönmetzler A, et al. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. J Geriatr Oncol. 1879;4068(14):299–306. doi:10.1016/j.jgo.2014.02.002

16.

Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematologic malignancy—a systematic review. Leuk Res. 2014;38:275–83.PubMedCrossRef

17.

Stauder R. The challenge of personalized risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Haematol. 2012;91:1333–43.CrossRef

18.

Stauder R, Wimazal F, Nösslinger T, Krieger O, Sperr WR, Sill H, et al. Individualized management and therapy of myelodysplastic syndromes. Wien Klin Wochenschr. 2008;120:523–37.PubMedCrossRef

19.

Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114:2393–400.PubMedCentralPubMedCrossRef

20.

Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. Scandinavian MDS group. A validated decision model for treating the anaemia of myelodysplatic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037–46.PubMedCrossRef

21.

Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, et al. Iron overload in myelodysplastic syndromes (MDS)—diagnosis, management, and response criteria: a proposal of the Austrian MDS Platform. Eur J Clin Invest. 2008;38:143–9.PubMedCentralPubMedCrossRef

22.

Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.PubMedCrossRef

23.

Fenaux P, Giagounidis A, Sellelag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.PubMedCrossRef

24.

List A, Dewald G, Bennet J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:456–65.CrossRef

25.

Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.PubMedCrossRef

26.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label phase III study. Lancet Oncol. 2009;10:223–32.PubMedCentralPubMedCrossRef

27.

Prébet T, Gore DS, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:475–83.CrossRef

28.

Pleyer L, Stauder R, Thaler J, Ludwig H, Pfeilstöcker M, Steinkirchner S, et al. Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients. Leuk Res. 2011;35(Suppl 1):450.

29.

Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38:475–83.PubMedCrossRef

30.

www.oegh.at/arbeitsgruppen/mds-plattform/aufgaben-ziele.html.

Titel: 10th anniversary of the Austrian MDS Platform: aims and ongoing projects
verfasst von: Sonja Burgstaller, MD
Peter Bettelheim
Otto Krieger
Sigrid Machherndl-Spandl
Thomas Nösslinger
Lisa Pleyer
Heinz Sill
Wolfgang R. Sperr
Reinhard Stauder
Peter Valent
Michael Pfeilstöcker
Publikationsdatum: 01.01.2015
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 1-2/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-014-0627-0

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2015

ÖGIM Flip

Elite level rhythmic gymnasts have significantly more and stronger pain than peers of similar age: a prospective study

Systematic implementation of clinical risk management in a large university hospital: the impact of risk managers

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer

Red cell distribution width: a novel prognostic factor of pulmonary embolism?

Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress